Physician profile
Scott A Mcham
NPI 1235170473
$3,052.08
in general payments reported to CMS, 2019-2025
49 companies · $302 in 2025
The $302 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $541 · 2020: $273 · 2021: $456 · 2022: $629 · 2023: $584 · 2024: $267 · 2025: $302.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,132 · Education: $20.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,132.45 |
| Education | $20.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $442.51 | 2019-2025 | Opdualag, Opdivo |
| Pfizer INC. | $197.21 | 2019-2025 | |
| Janssen Biotech, INC. | $159.43 | 2019-2023 | Erleada |
| Pharmacyclics LLC, An Abbvie Company | $152.16 | 2021-2023 | Epkinly, Imbruvica |
| Merck Sharp & Dohme LLC | $147.81 | 2019-2024 | Keytruda |
| Daiichi Sankyo INC. | $116.34 | 2020-2023 | Enhertu |
| Seagen INC. | $114.80 | 2020-2023 | Tukysa |
| Eisai INC. | $114.54 | 2020-2025 | |
| Abbvie INC. | $104.50 | 2019-2024 | |
| Celgene Corporation | $102.01 | 2019-2024 | Pomalyst, Reblozyl |
| Tersera Therapeutics LLC | $101.72 | 2021-2022 | |
| Novartis Pharmaceuticals Corporation | $94.26 | 2019-2022 | |
| Emd Serono, INC. | $92.05 | 2020-2023 | Bavencio |
| Gilead Sciences, INC. | $78.13 | 2021-2022 | |
| Aveo Pharmaceuticals, INC. | $72.18 | 2022-2025 | Fotivda |
Show all 49 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Scott Mcham listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.